Century Therapeutics, Inc. (IPSC)
Dopo ore:
| Chiusura precedente | 2,3800 |
| Aperto | 2,4700 |
| Denaro | 2,4800 x 300 |
| Domanda | 2,5100 x 100 |
| Min-Max giorno | 2,3500 - 2,5199 |
| Intervallo di 52 settimane | 1,2800 - 5,5100 |
| Volume | |
| Media Volume | 231.140 |
| Capitalizzazione | 211,252M |
| Beta (mensile su 5 anni) | 1,40 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,2200 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 12,80 |
GlobeNewswireCentury Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET. A replay of the event will be available on the “Events & Prese
- GlobeNewswire
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended second quarter 2023 with cash, cash equivalents, and investments of $301.0 million; Cash runway expected into 2026 – PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-d
